Ketamine Use in Child and Adolescent Psychiatry: Emerging Data in Treatment-Resistant Depression, Insights from Adults, and Future Directions.

IF 5.5 2区医学 Q1 PSYCHIATRY Current Psychiatry Reports Pub Date : 2023-08-01 DOI:10.1007/s11920-023-01432-w

Kaitlyn Ryan, Avinash Hosanagar

{"title":"Ketamine Use in Child and Adolescent Psychiatry: Emerging Data in Treatment-Resistant Depression, Insights from Adults, and Future Directions.","authors":"Kaitlyn Ryan, Avinash Hosanagar","doi":"10.1007/s11920-023-01432-w","DOIUrl":null,"url":null,"abstract":"Purpose of review: The following review will explore ketamine's antidepressant and antisuicidal properties in adults, review of what is known about ketamine's safety in children, and summarize the limited information we have on ketamine's role in treating depression and suicidal ideation in adolescents with depression. Future directions for ketamine's role in child psychiatry based on animal and adult studies will also be explored.Recent findings: Over the past 20 years, ketamine has emerged as a novel treatment for depression and suicidal ideation in adults. In recent years, these studies have been extended to adolescents. In 2021, the first placebo-controlled trial examining ketamine's antidepressant potential in adolescents was performed, demonstrating superior efficacy over midazolam. Initial studies suggest that ketamine functions as a rapidly acting antidepressant in adolescents. Case reports suggest that ketamine may also reduce suicidal ideation in this population. However, existing studies are small, and more research is needed to solidify these findings and inform clinical practice.","PeriodicalId":11057,"journal":{"name":"Current Psychiatry Reports","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Psychiatry Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11920-023-01432-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The following review will explore ketamine's antidepressant and antisuicidal properties in adults, review of what is known about ketamine's safety in children, and summarize the limited information we have on ketamine's role in treating depression and suicidal ideation in adolescents with depression. Future directions for ketamine's role in child psychiatry based on animal and adult studies will also be explored.

Recent findings: Over the past 20 years, ketamine has emerged as a novel treatment for depression and suicidal ideation in adults. In recent years, these studies have been extended to adolescents. In 2021, the first placebo-controlled trial examining ketamine's antidepressant potential in adolescents was performed, demonstrating superior efficacy over midazolam. Initial studies suggest that ketamine functions as a rapidly acting antidepressant in adolescents. Case reports suggest that ketamine may also reduce suicidal ideation in this population. However, existing studies are small, and more research is needed to solidify these findings and inform clinical practice.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

氯胺酮在儿童和青少年精神病学中的使用:难治性抑郁症的新数据，来自成年人的见解和未来方向。

综述目的:以下综述将探讨氯胺酮在成人中的抗抑郁和抗自杀特性，综述氯胺酮在儿童中的已知安全性，并总结氯胺酮在治疗青少年抑郁症和自杀意念方面的有限信息。在动物和成人研究的基础上，还将探讨氯胺酮在儿童精神病学中的作用的未来方向。最近的发现:在过去的20年里，氯胺酮已经成为一种治疗成人抑郁症和自杀意念的新方法。近年来，这些研究已扩展到青少年。2021年，进行了第一次安慰剂对照试验，研究氯胺酮在青少年中的抗抑郁潜力，证明其疗效优于咪达唑仑。初步研究表明氯胺酮在青少年中是一种速效抗抑郁药。病例报告显示氯胺酮也可能减少这一人群的自杀意念。然而，现有的研究规模很小，需要更多的研究来巩固这些发现并为临床实践提供信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Psychiatry Reports PSYCHIATRY-

CiteScore

11.30

自引率

3.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published research in psychiatry. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by psychiatric disorders. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as anxiety, medicopsychiatric disorders, and schizophrenia and other related psychotic disorders. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.